Roche (RHHBY) announced that the FDA has approved a label expansion of the asthma drug Xolair (omalizumab). The regulatory body approved the drug for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged one year and older with IgE-mediated food allergy. The FDA approval is based on positive data from the late-stage OUtMATCH study, which evaluated Xolair in patients aged between one and 55 years who are a ...